1. Home
  2. ESQ vs ABUS Comparison

ESQ vs ABUS Comparison

Compare ESQ & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Esquire Financial Holdings Inc.

ESQ

Esquire Financial Holdings Inc.

HOLD

Current Price

$113.60

Market Cap

941.0M

Sector

Finance

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.61

Market Cap

839.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ESQ
ABUS
Founded
2006
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Commercial Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
941.0M
839.5M
IPO Year
2017
2008

Fundamental Metrics

Financial Performance
Metric
ESQ
ABUS
Price
$113.60
$4.61
Analyst Decision
Buy
Strong Buy
Analyst Count
3
1
Target Price
$120.33
$5.00
AVG Volume (30 Days)
91.1K
1.5M
Earning Date
04-23-2026
05-14-2026
Dividend Yield
0.76%
N/A
EPS Growth
14.20
55.26
EPS
1.40
0.87
Revenue
N/A
$14,083,000.00
Revenue This Year
$35.15
N/A
Revenue Next Year
$39.09
$239.71
P/E Ratio
$80.15
$5.07
Revenue Growth
N/A
128.21
52 Week Low
$88.47
$3.04
52 Week High
$119.86
$5.10

Technical Indicators

Market Signals
Indicator
ESQ
ABUS
Relative Strength Index (RSI) 57.10 62.39
Support Level $104.40 $4.15
Resistance Level $118.39 $4.86
Average True Range (ATR) 3.29 0.16
MACD 0.35 0.03
Stochastic Oscillator 59.11 99.15

Price Performance

Historical Comparison
ESQ
ABUS

About ESQ Esquire Financial Holdings Inc.

Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: